BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, Koyabu M, Matsuyama M, Mori T, Kamihira T. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun. 2006;26:138-145. [PMID: 16337775 DOI: 10.1016/j.jaut.2005.10.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Ma W, Chen D. Immunological abnormalities in patients with primary biliary cholangitis. Clinical Science 2019;133:741-60. [DOI: 10.1042/cs20181123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
2 Park W, Rengaraj D, Kil DY, Kim H, Lee HK, Song KD. RNA-seq analysis of the kidneys of broiler chickens fed diets containing different concentrations of calcium. Sci Rep 2017;7:11740. [PMID: 28924246 DOI: 10.1038/s41598-017-11379-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Wang XS, Li YZ, Liu GZ. Gene cloning and fusion expression of human autoantigen Sp100 in yeasts. Shijie Huaren Xiaohua Zazhi 2006; 14(8): 758-762 [DOI: 10.11569/wcjd.v14.i8.758] [Reference Citation Analysis]
4 Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479. [PMID: 23777462 DOI: 10.3109/08916934.2013.801461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
5 Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008;8:9-15. [PMID: 18385935 DOI: 10.1007/s10238-008-0150-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chuang YH, Ridgway WM, Ueno Y, Gershwin ME. Animal models of primary biliary cirrhosis. Clin Liver Dis. 2008;12:333-47; ix. [PMID: 18456184 DOI: 10.1016/j.cld.2008.02.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
7 Bindra D, Mishra RK. In Pursuit of Distinctiveness: Transmembrane Nucleoporins and Their Disease Associations. Front Oncol 2021;11:784319. [PMID: 34970494 DOI: 10.3389/fonc.2021.784319] [Reference Citation Analysis]
8 Sakuma S, D'Angelo MA. The roles of the nuclear pore complex in cellular dysfunction, aging and disease. Semin Cell Dev Biol 2017;68:72-84. [PMID: 28506892 DOI: 10.1016/j.semcdb.2017.05.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 11.2] [Reference Citation Analysis]
9 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629 [PMID: 20677333 DOI: 10.3748/wjg.v16.i29.3616] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
11 Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2007;23:255-262. [PMID: 17414840 DOI: 10.1097/MOG.0b013e328034f234] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
12 Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642-651. [PMID: 25243383 DOI: 10.1111/liv.12690] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
13 Selmi C, Cocchi CA, Zuin M, Gershwin ME. The Chemical Pathway to Primary Biliary Cirrhosis. Clinic Rev Allerg Immunol 2009;36:23-9. [DOI: 10.1007/s12016-008-8089-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
14 Chantran Y, Ballot E, Johanet C. Autoantibodies in primary biliary cirrhosis: Antinuclear envelope autoantibodies. Clinics and Research in Hepatology and Gastroenterology 2014;38:256-8. [DOI: 10.1016/j.clinre.2013.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Nakamura M, Komori A, Ito M, Kondo H, Aiba Y, Migita K, Nagaoka S, Ohata K, Yano K, Abiru S. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res. 2007;37 Suppl 3:S412-S419. [PMID: 17931196 DOI: 10.1111/j.1872-034x.2007.00244.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
16 Medina JF. Role of the Anion Exchanger 2 in the Pathogenesis and Treatment of Primary Biliary Cirrhosis. Dig Dis 2011;29:103-12. [DOI: 10.1159/000324144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
17 Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 Suppl S1:71-90. [PMID: 24397841 DOI: 10.1111/hepr.12270] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
18 Frank M, Manček-keber M, Kržan M, Sodin-šemrl S, Jerala R, Iglič A, Rozman B, Kralj-iglič V. Prevention of microvesiculation by adhesion of buds to the mother cell membrane — A possible anticoagulant effect of healthy donor plasma. Autoimmunity Reviews 2008;7:240-5. [DOI: 10.1016/j.autrev.2007.11.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
19 Sfakianaki O, Tzardi M, Voumvouraki A, Afgoustaki A, Koulentaki M, Kouroumalis E. Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis. World J Hepatol 2013; 5(10): 568-576 [PMID: 24179616 DOI: 10.4254/wjh.v5.i10.568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019;105:102328. [PMID: 31548157 DOI: 10.1016/j.jaut.2019.102328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
21 Brahim I, Brahim I, Hazime R, Admou B. [Autoimmune hepatitis: Immunological diagnosis]. Presse Med 2017;46:1008-19. [PMID: 28919271 DOI: 10.1016/j.lpm.2017.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Cristoferi L, Gerussi A, Invernizzi P. Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. Liver Int 2021;41:432-5. [PMID: 34542229 DOI: 10.1111/liv.14791] [Reference Citation Analysis]
23 Ben Lamine Z, Ben Jazia I, Ben Ahmed M, Ben Slama A, Baccouche A, Slama F, Jemaa A, Ghedira I, Mankaï A. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis. Arab J Gastroenterol 2021:S1687-1979(21)00028-9. [PMID: 34090832 DOI: 10.1016/j.ajg.2021.05.006] [Reference Citation Analysis]
24 Kouroumalis E, Notas G. Primary biliary cirrhosis: From bench to bedside. World J Gastrointest Pharmacol Ther 2015; 6(3): 32-58 [PMID: 26261733 DOI: 10.4292/wjgpt.v6.i3.32] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
25 Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008;30:5-11. [PMID: 18194728 DOI: 10.1016/j.jaut.2007.11.009] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 7.6] [Reference Citation Analysis]
26 Yang CY, Leung PS, Yang GX, Kenny TP, Zhang W, Coppel R, Norman GL, Ansari AA, Mackay IR, Worman HJ. Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent. Clin Exp Immunol. 2012;168:261-267. [PMID: 22519587 DOI: 10.1111/j.1365-2249.2012.04577.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
27 Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, Koyabu M, Yokoyama T, Migita K, Daikoku M, Abiru S, Yatsuhashi H, Takezaki E, Masaki N, Sugi K, Honda K, Adachi H, Nishi H, Watanabe Y, Nakamura Y, Shimada M, Komatsu T, Saito A, Saoshiro T, Harada H, Sodeyama T, Hayashi S, Masumoto A, Sando T, Yamamoto T, Sakai H, Kobayashi M, Muro T, Koga M, Shums Z, Norman GL, Ishibashi H. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27. [PMID: 17187436 DOI: 10.1002/hep.21472] [Cited by in Crossref: 251] [Cited by in F6Publishing: 208] [Article Influence: 16.7] [Reference Citation Analysis]
28 E G, Yang BG, Basang WD, Zhu YB, An TW, Luo XL. Screening for signatures of selection of Tianzhu white yak using genome-wide re-sequencing. Anim Genet 2019;50:534-8. [PMID: 31246332 DOI: 10.1111/age.12817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Haldar D, Janmohamed A, Plant T, Davidson M, Norman H, Russell E, Serevina O, Chung K, Qamar K, Gunson B, Hansen B, Richter A, Trivedi PJ, Hirschfield GM. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver Int 2021;41:535-44. [PMID: 33022821 DOI: 10.1111/liv.14688] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Duarte-Rey C, Bogdanos D, Yang CY, Roberts K, Leung PS, Anaya JM, Worman HJ, Gershwin ME. Primary biliary cirrhosis and the nuclear pore complex. Autoimmun Rev. 2012;11:898-902. [PMID: 22487189 DOI: 10.1016/j.autrev.2012.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
31 Aiba Y, Nakamura M, Joshita S, Inamine T, Komori A, Yoshizawa K, Umemura T, Horie H, Migita K, Yatsuhashi H. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46:1203-1212. [PMID: 21594562 DOI: 10.1007/s00535-011-0417-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
32 Yamagiwa S, Kamimura H, Takamura M, Aoyagi Y. Autoantibodies in primary biliary cirrhosis: Recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol 2014; 20(10): 2606-2612 [PMID: 24627596 DOI: 10.3748/wjg.v20.i10.2606] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
33 Deane S, Meyers FJ, Gershwin ME. On reversing the persistence of memory: Hematopoietic stem cell transplant for autoimmune disease in the first ten years. Journal of Autoimmunity 2008;30:180-96. [DOI: 10.1016/j.jaut.2007.12.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
34 Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008;3:1. [PMID: 18215315 DOI: 10.1186/1750-1172-3-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
35 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(7): 702-708 [DOI: 10.11569/wcjd.v14.i7.702] [Reference Citation Analysis]